Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

NCT00871910 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Lymphoma, Non-Hodgkin
Multiple Myeloma

Interventions

DRUG: SCH 727965
DRUG: SCH 727965
DRUG: SCH 727965
DRUG: SCH 727965
DRUG: Aprepitant
DRUG: Ondansetron
DRUG: Dexamethasone

Sponsor

Merck Sharp & Dohme LLC